

21 January 2016

December 2015 Quarterly Update and Appendix 4C

Highlights:

- Strong total revenues in excess of \$1.2 million year to date (2014: \$801,000);
- Half year profit guidance of around \$370,000, 75% higher than same period last year (2014: \$213,000);
- Solid closing cash and debtors position at end of the half year.

Bioxyne Limited (the Company) reported a net operating cash outflow for the quarter of \$80,000. The net outflow was largely a result in the timing difference of sales made during the December quarter and actual sales receipts (trade receivables) versus payments for cost of goods and other operational expenditure.

Sales of PCC in the December quarter were in excess of \$440,000 (2014: \$365,000). Year to date 31 December 2015 sales were in excess of \$1.2 million (2014: \$801,000).

As a result of these increased sales the Company expects to report an unaudited YTD 31 December 2015 net profit of around \$370,000 which is 75% higher than the same period last year (2014: \$213,000) with a closing cash balance of \$1,184,000 (30 June 2015: \$958,469).

As at 31 December 2015 the Company had current trade receivables of \$390,000 which will be received in January and February 2016.

The Company has completed the half year ended 31 December 2015 in a strong financial position. The Board continues to effectively manage operational expenditure and sales opportunities to maximise sales and profits.

In calender year 2015, the Company's growth plan was delayed by prolonged incomplete commercial negotiations. In 2016 the Company intends to implement a business plan to widen the distribution of our probiotics business.

The Company continues to seek opportunities to leverage on the Company's proprietary Intellectual Property of our *lactobacillus fermentum PCC* strain of Probiotics and distribution of other Over the Counter (OTC) products

For more information, please contact:

Tony Ho
Chairman
Bioxyne Limited

Mobile: +61 417 345 839

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity	
Bioxyne Limited	
ABN	Quarter ended ("current quarter")
97 084 464 193	31 December 2015

Consolidated statement of cash flows

		Current quarter	Year to date
		\$A'000	(6 months)
Cash f	lows related to operating activities		\$A'000
1.1	Receipts from customers	356	1,018
1.2	Payments for		
	(a) staff costs	-	-
	(b) advertising and marketing	(26)	(26)
	(c) Royalty payments	-	-
	(d) leased assets	-	-
	(e) cost of goods sold	(185)	(523)
	(f) other working capital	(226)	(282)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature		
	received	1	1
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other (R&D Tax Concession Proceeds)	-	-
	Net operating cash flows	(80)	188

⁺ See chapter 19 for defined terms.

		Current quarter \$A'000	Year to date (6 months) \$A'000
1.8	Net operating cash flows (carried forward)	(80)	188
	Cash flows related to investing activities		
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property (d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities		-
1.12	Loans repaid by other entities	-	_
1.13	Other	-	-
	Net investing cash flows	-	-
1.14	Total operating and investing cash flows	(80)	188
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares, options, etc.	-	-
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from issue of convertible notes	-	-
1.18	(Repayment)/Proceeds of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Cost of issuing equity	-	-
	Net financing cash flows	-	<u>-</u>
	Net increase (decrease) in cash held	(80)	188
1.21	Cash at beginning of quarter/year to date	1,319	958
1.22	Exchange rate adjustments	(55)	38
1.23	Cash at end of quarter	1,184	1,184

⁺ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000	
1.24	Aggregate amount of payments to the parties included in item 1.2	38	
1.25	Aggregate amount of loans to the parties included in item 1.11	-	
1.26	Explanation necessary for an understanding of the transactions		
	N/A		
Non-cash financing and investing activities			
2.1	Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows		
	N/A		
2.2	Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest		
	N/A		

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

⁺ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	1,184	1,319
4.2	Deposits at call	-	-
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
	Total: cash at end of quarter (item 1.23)	1,184	1,319

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	-	-
5.2	Place of incorporation or registration	-	-
5.3	Consideration for acquisition or disposal	-	-
5.4	Total net liability	-	-
5.5	Nature of business	-	-

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:

(Director/Company secretary)

Date: 21 January 2016

Print name:

Jarrod T White

⁺ See chapter 19 for defined terms.

Notes

- 1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
- 2. The definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
- 3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

⁺ See chapter 19 for defined terms.